Angiogenic profile of hematologic malignancies.
. | . | . | Angiogenic Receptors . | ||||
---|---|---|---|---|---|---|---|
Malignancy . | Pro-Angiogenic Molecules . | MVD . | VEGFR-1 . | VEGFR-2 . | FGF-R . | Clinical/Biological Correlation . | Reference . |
Abbreviations: CR, complete remission; s, serum or plasma; u, urinary; c, cellular; CRP, C-reactive protein; B2M, beta2-microglobulin; LN, lymph node; MMM, myelofibrosis with myeloid metaplasia; Unk, unknown; IL-6, interleukin-6; ALIP, abnormal localized immature precursors; AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin's lymphoma; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; MVD, microvessel density; OS, overall survival; DFS, disease-free survival; BM, bone marrow; VEGF, vascular endothelial growth factor; FGF, fibroblast growth factor; bFGF, basic FGF; SDF-1, stromal-derived factor 1 | |||||||
* Denotes independent prognostic factor. | |||||||
AML | s,cVEGF* | ↑BM | ++ | +/- | Unk | Leukocytosis; ↓CR*, OS*, DFS* (VEGF) | 68,69,71,72,78, 94-96 |
cMMP 2,9 | |||||||
sFGF | |||||||
sSDF-1 | |||||||
MDS | VEGF | ↑BM | ++ | +/- | Unk | Survival (VEGF); | 69,72,96-9 |
cMMP-2,cMMP-9 | blast % (MVD); | ||||||
sSDF-1 | TNFα generation; ALIP | ||||||
sIL-8 | |||||||
MMM | ↑BM | Unk | Unk | Unk | Survival (MVD)* | 99 | |
Splenomegaly (MVD) | |||||||
Myeloma | s,cVEGF | ↑BM | - | - | + | Overall survival (MVD) | 20,74,100-102 |
sbFGF* | Trisomy 13, CRP, B2M | ||||||
cMMP-2 | ↑ stromal IL-6 | ||||||
ALL | s,ubFGF | ↑BM | Unk | Unk | Unk | 72,103,104 | |
sSDF-1 | |||||||
cMMP-2,cMMP-9 | |||||||
NHL | sbFGF* | ↑LN | + | +/- | Unk | Survival* (VEGF, FGF) | 75-77,105,106 |
s,cVEGF* | High grade histology (VEGF, FGF) | ||||||
Advanced stage | |||||||
CLL | s,cVEGF | ↑BM | Unk | Unk | - | Advanced stage (MVD, VEGF) | 72,73,107-109 |
c,sbFGF | Time to progression (VEGF) | ||||||
sSDF-1 | Fludarabine resistance (cFGF) | ||||||
CML | sVEGF | ↑BM | Unk | Unk | + | 72,73 | |
c,sbFGF | |||||||
sSDF-1 |
. | . | . | Angiogenic Receptors . | ||||
---|---|---|---|---|---|---|---|
Malignancy . | Pro-Angiogenic Molecules . | MVD . | VEGFR-1 . | VEGFR-2 . | FGF-R . | Clinical/Biological Correlation . | Reference . |
Abbreviations: CR, complete remission; s, serum or plasma; u, urinary; c, cellular; CRP, C-reactive protein; B2M, beta2-microglobulin; LN, lymph node; MMM, myelofibrosis with myeloid metaplasia; Unk, unknown; IL-6, interleukin-6; ALIP, abnormal localized immature precursors; AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin's lymphoma; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; MVD, microvessel density; OS, overall survival; DFS, disease-free survival; BM, bone marrow; VEGF, vascular endothelial growth factor; FGF, fibroblast growth factor; bFGF, basic FGF; SDF-1, stromal-derived factor 1 | |||||||
* Denotes independent prognostic factor. | |||||||
AML | s,cVEGF* | ↑BM | ++ | +/- | Unk | Leukocytosis; ↓CR*, OS*, DFS* (VEGF) | 68,69,71,72,78, 94-96 |
cMMP 2,9 | |||||||
sFGF | |||||||
sSDF-1 | |||||||
MDS | VEGF | ↑BM | ++ | +/- | Unk | Survival (VEGF); | 69,72,96-9 |
cMMP-2,cMMP-9 | blast % (MVD); | ||||||
sSDF-1 | TNFα generation; ALIP | ||||||
sIL-8 | |||||||
MMM | ↑BM | Unk | Unk | Unk | Survival (MVD)* | 99 | |
Splenomegaly (MVD) | |||||||
Myeloma | s,cVEGF | ↑BM | - | - | + | Overall survival (MVD) | 20,74,100-102 |
sbFGF* | Trisomy 13, CRP, B2M | ||||||
cMMP-2 | ↑ stromal IL-6 | ||||||
ALL | s,ubFGF | ↑BM | Unk | Unk | Unk | 72,103,104 | |
sSDF-1 | |||||||
cMMP-2,cMMP-9 | |||||||
NHL | sbFGF* | ↑LN | + | +/- | Unk | Survival* (VEGF, FGF) | 75-77,105,106 |
s,cVEGF* | High grade histology (VEGF, FGF) | ||||||
Advanced stage | |||||||
CLL | s,cVEGF | ↑BM | Unk | Unk | - | Advanced stage (MVD, VEGF) | 72,73,107-109 |
c,sbFGF | Time to progression (VEGF) | ||||||
sSDF-1 | Fludarabine resistance (cFGF) | ||||||
CML | sVEGF | ↑BM | Unk | Unk | + | 72,73 | |
c,sbFGF | |||||||
sSDF-1 |